Long-term Benzodiazepine Treatment in Patients with Psychotic Disorders Attending a Mental Health Service in Rural Greece

INTRODUCTION

Long-term benzodiazepine (BZD) treatment in patients with mental disorders is widespread in clinical practice although it is not recommended by international clinical guidelines and medical authorities.[1] In a recent systematic review of 41 register-based studies on definitions and prevalence of long-term BZD use, Kurko et al.[2] found a mean prevalence of 24% (ranged from 6% to 76%). Another recent study which comprised data from 7 European electronic health-care databases found the prevalence of BZD prescription to increase steadily with age and to be 2-fold higher in women than in men in all databases. A median of 18% of patients received 10 or more prescriptions in a year.[3]

In patients with schizophrenia and related disorders, BZDs such as diazepam and lorazepam are frequently co-prescribed to standard antipsychotic drug treatment in clinical practice.[4567] It has been suggested that as high as 95% of patients with schizophrenia receive a short-term BZD regimen at some point during their illness.[8] These compounds are used for managing hostile and aggressive behavior in patients with psychotic disorders. Other indications include anxiety, insomnia, and akathisia. However, recent guidelines do not recommend long-term BZD use in patients with schizophrenia. There are concerns that such use may increase the risk of dependence and may further deteriorate cognitive function.[9] Moreover, recent evidence suggests that BZD use by patients with schizophrenia is associated with increased mortality risk.[10]

Many large-scale studies on BZD prescription used data derived from national or regional databases whereas information on the use of BZD by patients with schizophrenia and related psychoses in general population-based samples is limited. A recent study from Finland reported a rate of BZD use by a sample of 55 patients with schizophrenia as high as 42% whereas 24% of patients were receiving BZD regularly.[11] The aim of the present study was to explore the long-term BZD use by community-dwelling patients with psychotic disorders, who regularly attend a mental health service within the primary care setting in rural and remote areas of Greece and to enquire for factors that may be associated with such use.

MATERIALS AND METHODS

The multidisciplinary Mobile Mental Health Unit of the prefectures of Ioannina and Thesprotia (MMHU I-T), Northwest Greece, has been established in 2007 and delivers services to a population grossly estimated at 100,000 inhabitants in rural and remote areas, mostly mountainous areas. Its contribution to the care of patients living in those areas has been reported elsewhere.[121314] The care of patients with psychotic disorders is a priority for the MMHU I-T. The MMHU I-T uses the resources of the primary care system but may also visit patients at their homes when needed.

Information for all patients with psychotic disorders who were regularly attending follow-up appointments with the MMHU I-T during 1-year period (2015) was obtained from our database, including demographic data (age and gender), clinical information (illness duration, number of admissions, and history of alcohol/substance abuse) and from prescription records. History of alcohol and substance abuse was determined according to the patients’ or family members’ accounts, or according to primary care records, without the use of a structured instrument. Patients’ psychopathology was not measured in detail as its association with BZD use could not be determined. Reason for the initial BZD prescription could not be accurately retrieved. Chronic BZD use was defined as regular use for at least 6 months within the year of the study. All the procedures were approved by the Institutional Board.

The sample comprised 77 stabilized, community-dwelling patients with schizophrenia and related disorders, according to the International Classification of Disease, 10^th Revision that had been engaged to treatment with the MMHU I-T (i.e., they regularly attended scheduled follow-up appointments). Most patients (n=67, 87%) were receiving drug treatment before engagement with the MMHU I-T. Thus, prescribing patterns corresponded to the practice of several treatment settings and psychiatrists that had examined and treated those patients before they engage to treatment with the MMHU I-T. Most patients were chronic cases, and only 5 (6.5%) were first episode patients.

We reported our data separately for patients on BZD treatment and for those who did not receive BZD. Comparisons between the two patient groups were performed using Chi-square or Fisher's exact test for binary variables, and Student's t-test for continuous variables. P < 0.05 was considered statistically significant. The IBM SPSS Statistics for Windows, version 23 (IBM Corp., Armonk, N.Y., USA) was used to perform all analyses.

RESULTS

Most patients with psychotic disorders were male (66.2%) and middle-aged (mean age 54.2 years, median 54, standard deviation [SD] 14.94). The mean illness duration was 25.3 years (median 28 and SD 14.16). All but two patients were regularly refilling their antipsychotic prescriptions. The majority of the patients (n = 44, 57.1%) were receiving atypical antipsychotics whereas 18.2% of patients were receiving a concomitant antidepressant [Table 1]. A proportion of patients (n = 10, 13%) were receiving antipsychotic combination. Long-acting injectable antipsychotic was prescribed in 13 (16.9%) patients, and 5 (6.5%) patients were on clozapine treatment, but only 2 on clozapine monotherapy.

Table 1 Patients’ medications

From the total of 77 engaged patients, 30 (39%) were regularly prescribed BZDs in long term, as part of their treatment regimen. Table 2 shows the correlations of chronic BZD use with several patients’ characteristics. Prescribed BZDs were mostly diazepam and lorazepam, in 13 cases each (43.3% of total patients in BZD treatment). The mean daily dose of these compounds was 13 mg and 3.77 mg, respectively. Statistical analysis showed a significant correlation of long-term BZD use with the history of alcohol/substance abuse (P = 0.013). Most patients were receiving BZD continuously for several years, and the mean dose was steady within this interval.

Table 2 Correlations of patients’ demographic and clinical characteristics with chronic benzodiazepine use

DISCUSSION

In this study, from the total of 77 engaged patients with psychotic disorders, 30 (39%) were regularly prescribed BZDs in long term. This rate lies within the range of the reported rates in literature which vary widely, from 16% to 79.2%, depending on definition, the treatment setting, and prescribing habits across countries.[4567] It appears that when BZDs are prescribed for some period in the course of a psychotic disorder, their use commonly exceeds the recommended interval and then becomes a regular part of the chronic treatment regimen. Given the sedative effects of BZDs and their effects on cognitive function, their long-term use is discouraged by medical authorities.[115] However, this may not be the case of everyday clinical practice.[4567]

An important finding of the present study is that the mean BZD dose was stable over time and rather moderate although somewhat higher than in the study by Wu et al.[6] This finding raises questions about the induction of tolerance in such patients, at these doses. It may be interpreted as that the therapeutic benefits of BZD treatment may be maintained over long periods of time in a proportion of patients.[9] Moreover, patients may find the sedative effects of BZD pleasant[16] and may resist to dose reduction, or discontinuation; or dependence may have occurred, which renders discontinuation too difficult.[17] These issues should be taken into account by clinicians when prescribing BZD, especially in patients with a history of substance abuse. In addition, it is possible that clinicians are reluctant to change the treatment regimen in chronic, stabilized patients with psychotic disorders to avoid the risk of decompensation.[6]

Statistical analysis showed that long-term BZD prescription was correlated with a history of alcohol/substance abuse. This finding implies that such patients are prone to regular use after initial prescription. The administration of BZD in long term, at steady doses, may have the desirable sedative and relaxant effects on those patients and importantly this use is medically monitored and not uncontrolled or illicit. This is in accordance with the recommendation of the British authorities that in patients with a history of drug dependence, a conscious decision to continue BZD treatment may be more reasonable than the alternatives.[9] Perhaps, in those cases, long-term BZD treatment in moderate and stable dose could be acceptable and may prevent patients from seeking substances or alcohol. However, cautious prescribing is always warranted as there is some evidence that BZD use by patients with co-occurring severe mental illness and a substance use disorder increases the likelihood of BZD abuse.[18]

In our study, neither patients’ age nor gender was associated with long-term BZD treatment. In a recent European study which comprised data from 7 electronic health-care databases, it found the prevalence of BZD prescription to increase steadily with age and to be 2-fold higher in women than in men in all databases.[3] These discrepancies are probably explained due to differences in the samples of patients. The study of Huerta et al.[3] included prescriptions in patients with a broad range of diagnoses whereas our sample included patients with psychotic disorders. This may mean that BZD prescription patterns in patients with psychotic disorders differ from other diagnoses’ patients.

There is a paucity of research on the use of psychiatric medications by patients with schizophrenia and related psychoses in general population-based samples.[11] This study addresses the important issue of regular BZD prescription in rural community-dwelling patients with psychotic disorders. It is well documented that mental health-care services remain inaccessible to rural communities for several reasons, including geographical barriers, economic constraints, and lack of resources, such as insufficient number of trained professionals.[1920] Mental health treatment delivery in rural and remote areas is challenging, and the results of this study are relevant for everyday clinical practice in those underserved areas.

CONCLUSIONS

In our sample of community-dwelling patients with psychotic disorders attending a community mental health service in rural areas, a large proportion received BZD as part of their regular treatment regimen, and a history of alcohol/substance abuse was associated with regular BZD use. Although the generalizability of our findings may be limited by differences in prescribing habits among different settings and countries, they could inform clinical practice in rural settings, given the lack of studies in general population-based samples of patients. There is a need for research on mental health treatment in rural, remote, and frequently underserved areas, where mental health care may be inaccessible. Community mental health services in those areas may facilitate access to quality treatment, in collaboration with primary care providers.